Based on these findings, this group was one of the first to describe the putative order of molecular alterations in gliomas incorporated in the WHO 2016 classification with IDH point mutations, TERT promoter mutations, and 1p19q co-deletion as early events. This evidence concerns the gene IDH2 and central nervous system cancer.